ZA200410046B - Molecular antigen arrays using a virus like particle derived from the AP205 coat protein. - Google Patents

Info

Publication number

ZA200410046B

ZA200410046B ZA200410046A ZA200410046A ZA200410046B ZA 200410046 B ZA200410046 B ZA 200410046B ZA 200410046 A ZA200410046 A ZA 200410046A ZA 200410046 A ZA200410046 A ZA 200410046A ZA 200410046 B ZA200410046 B ZA 200410046B

Authority

ZA

South Africa

Prior art keywords

seq

composition

protein

amino acid

antigen

Prior art date

2002-07-17

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 title claims description 242
• 108091007433 antigens Proteins 0.000 title claims description 233
• 102000036639 antigens Human genes 0.000 title claims description 233
• 239000002245 particle Substances 0.000 title claims description 114
• 241000700605 Viruses Species 0.000 title claims description 29
• 101710132601 Capsid protein Proteins 0.000 title description 68
• 101710094648 Coat protein Proteins 0.000 title description 66
• 101710125418 Major capsid protein Proteins 0.000 title description 66
• 101710141454 Nucleoprotein Proteins 0.000 title description 66
• 101710083689 Probable capsid protein Proteins 0.000 title description 66
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 title description 64
• 238000003491 array Methods 0.000 title description 6
• 108090000623 proteins and genes Proteins 0.000 claims description 218
• 102000004169 proteins and genes Human genes 0.000 claims description 189
• 235000018102 proteins Nutrition 0.000 claims description 185
• 239000000203 mixture Substances 0.000 claims description 181
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 164
• 235000001014 amino acid Nutrition 0.000 claims description 146
• 210000004027 cell Anatomy 0.000 claims description 103
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 93
• 230000000890 antigenic effect Effects 0.000 claims description 90
• 230000028993 immune response Effects 0.000 claims description 88
• 239000012634 fragment Substances 0.000 claims description 78
• 229960005486 vaccine Drugs 0.000 claims description 78
• 150000001413 amino acids Chemical class 0.000 claims description 77
• 238000000034 method Methods 0.000 claims description 77
• 241000282414 Homo sapiens Species 0.000 claims description 71
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 68
• 239000013598 vector Substances 0.000 claims description 64
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 55
• 201000010099 disease Diseases 0.000 claims description 48
• 230000003053 immunization Effects 0.000 claims description 47
• 229920001184 polypeptide Polymers 0.000 claims description 47
• 238000002649 immunization Methods 0.000 claims description 40
• 206010028980 Neoplasm Diseases 0.000 claims description 39
• 239000013566 allergen Substances 0.000 claims description 39
• 241000588724 Escherichia coli Species 0.000 claims description 38
• 230000004044 response Effects 0.000 claims description 36
• 238000006467 substitution reaction Methods 0.000 claims description 35
• 241001465754 Metazoa Species 0.000 claims description 32
• 125000000539 amino acid group Chemical group 0.000 claims description 29
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 28
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 28
• 238000004519 manufacturing process Methods 0.000 claims description 28
• 206010020751 Hypersensitivity Diseases 0.000 claims description 25
• 239000002671 adjuvant Substances 0.000 claims description 25
• 108020003175 receptors Proteins 0.000 claims description 24
• 229960004784 allergens Drugs 0.000 claims description 23
• 239000003814 drug Substances 0.000 claims description 23
• 201000011510 cancer Diseases 0.000 claims description 22
• 229940079593 drug Drugs 0.000 claims description 22
• 102000039446 nucleic acids Human genes 0.000 claims description 22
• 108020004707 nucleic acids Proteins 0.000 claims description 22
• 150000007523 nucleic acids Chemical class 0.000 claims description 22
• 239000002773 nucleotide Substances 0.000 claims description 20
• 125000003729 nucleotide group Chemical group 0.000 claims description 20
• 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 19
• 230000003252 repetitive effect Effects 0.000 claims description 18
• 102100023688 Eotaxin Human genes 0.000 claims description 17
• 108010047909 Resistin Proteins 0.000 claims description 16
• 102000007156 Resistin Human genes 0.000 claims description 16
• 230000007815 allergy Effects 0.000 claims description 16
• 210000004899 c-terminal region Anatomy 0.000 claims description 16
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 16
• 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 15
• 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 15
• 239000007771 core particle Substances 0.000 claims description 15
• 208000035473 Communicable disease Diseases 0.000 claims description 14
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 14
• 101710139422 Eotaxin Proteins 0.000 claims description 13
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
• 239000002253 acid Substances 0.000 claims description 12
• 208000035475 disorder Diseases 0.000 claims description 12
• 108010064733 Angiotensins Proteins 0.000 claims description 11
• 239000005556 hormone Substances 0.000 claims description 11
• 229940088597 hormone Drugs 0.000 claims description 11
• 239000004471 Glycine Substances 0.000 claims description 10
• 239000003053 toxin Substances 0.000 claims description 10
• 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 9
• 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 9
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
• 208000006673 asthma Diseases 0.000 claims description 9
• 108010025832 RANK Ligand Proteins 0.000 claims description 8
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 8
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
• 231100000765 toxin Toxicity 0.000 claims description 8
• 108700012359 toxins Proteins 0.000 claims description 8
• 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 7
• 102000014128 RANK Ligand Human genes 0.000 claims description 7
• 208000026935 allergic disease Diseases 0.000 claims description 7
• 206010022000 influenza Diseases 0.000 claims description 7
• 238000002360 preparation method Methods 0.000 claims description 7
• 231100000167 toxic agent Toxicity 0.000 claims description 7
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 6
• 102000015427 Angiotensins Human genes 0.000 claims description 6
• 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims description 6
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
• 229960002715 nicotine Drugs 0.000 claims description 6
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 6
• 102000015439 Phospholipases Human genes 0.000 claims description 5
• 108010064785 Phospholipases Proteins 0.000 claims description 5
• 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 claims description 5
• 125000003277 amino group Chemical group 0.000 claims description 5
• 230000001976 improved effect Effects 0.000 claims description 5
• 230000001939 inductive effect Effects 0.000 claims description 5
• 201000001441 melanoma Diseases 0.000 claims description 5
• 230000008569 process Effects 0.000 claims description 5
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 4
• 108050003558 Interleukin-17 Proteins 0.000 claims description 4
• 102000013691 Interleukin-17 Human genes 0.000 claims description 4
• 239000004472 Lysine Substances 0.000 claims description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
• RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 3
• 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
• 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
• 206010003402 Arthropod sting Diseases 0.000 claims description 3
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 3
• 108090000176 Interleukin-13 Proteins 0.000 claims description 3
• 102000003816 Interleukin-13 Human genes 0.000 claims description 3
• 108010002616 Interleukin-5 Proteins 0.000 claims description 3
• 108090001007 Interleukin-8 Proteins 0.000 claims description 3
• 102000004890 Interleukin-8 Human genes 0.000 claims description 3
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 229960005181 morphine Drugs 0.000 claims description 3
• 239000003440 toxic substance Substances 0.000 claims description 3
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 2
• 229930195730 Aflatoxin Natural products 0.000 claims description 2
• XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 claims description 2
• 101800004538 Bradykinin Proteins 0.000 claims description 2
• 102400000967 Bradykinin Human genes 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
• 108010036395 Endoglin Proteins 0.000 claims description 2
• 102100037241 Endoglin Human genes 0.000 claims description 2
• 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
• 241000711549 Hepacivirus C Species 0.000 claims description 2
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 2
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 2
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
• 208000002366 Nut Hypersensitivity Diseases 0.000 claims description 2
• 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 2
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
• 102100022831 Somatoliberin Human genes 0.000 claims description 2
• 101710142969 Somatoliberin Proteins 0.000 claims description 2
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 2
• 101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims description 2
• 108060008724 Tyrosinase Proteins 0.000 claims description 2
• 108091008605 VEGF receptors Proteins 0.000 claims description 2
• 239000005409 aflatoxin Substances 0.000 claims description 2
• 229940025084 amphetamine Drugs 0.000 claims description 2
• 239000003242 anti bacterial agent Substances 0.000 claims description 2
• 230000001093 anti-cancer Effects 0.000 claims description 2
• 229940088710 antibiotic agent Drugs 0.000 claims description 2
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
• 210000000481 breast Anatomy 0.000 claims description 2
• 229960003920 cocaine Drugs 0.000 claims description 2
• 229960004126 codeine Drugs 0.000 claims description 2
• 229960002069 diamorphine Drugs 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 2
• 229960002428 fentanyl Drugs 0.000 claims description 2
• 235000020932 food allergy Nutrition 0.000 claims description 2
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
• 229940100602 interleukin-5 Drugs 0.000 claims description 2
• 210000003734 kidney Anatomy 0.000 claims description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 2
• 229960001252 methamphetamine Drugs 0.000 claims description 2
• 229960001344 methylphenidate Drugs 0.000 claims description 2
• 239000002062 molecular scaffold Substances 0.000 claims description 2
• 201000010854 nut allergy Diseases 0.000 claims description 2
• 201000000849 skin cancer Diseases 0.000 claims description 2
• 230000004936 stimulating effect Effects 0.000 claims description 2
• CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 claims description 2
• CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 claims description 2
• 229950010357 tetrodotoxin Drugs 0.000 claims description 2
• 230000004962 physiological condition Effects 0.000 claims 4
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
• XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
• UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 1
• 241000237519 Bivalvia Species 0.000 claims 1
• 241000237505 Chlamys Species 0.000 claims 1
• 101150029707 ERBB2 gene Proteins 0.000 claims 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 1
• 102000000743 Interleukin-5 Human genes 0.000 claims 1
• 108010010995 MART-1 Antigen Proteins 0.000 claims 1
• 102000016200 MART-1 Antigen Human genes 0.000 claims 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
• CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 1
• 102000003425 Tyrosinase Human genes 0.000 claims 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
• 229940102884 adrenalin Drugs 0.000 claims 1
• 235000020639 clam Nutrition 0.000 claims 1
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
• 229960004242 dronabinol Drugs 0.000 claims 1
• 229940011871 estrogen Drugs 0.000 claims 1
• 239000000262 estrogen Substances 0.000 claims 1
• 229940028334 follicle stimulating hormone Drugs 0.000 claims 1
• 229940096397 interleukin-8 Drugs 0.000 claims 1
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
• 239000000186 progesterone Substances 0.000 claims 1
• 229960003387 progesterone Drugs 0.000 claims 1
• QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims 1
• 102200021395 rs3739168 Human genes 0.000 claims 1
• 229960003604 testosterone Drugs 0.000 claims 1
• 102000003390 tumor necrosis factor Human genes 0.000 claims 1
• 238000005859 coupling reaction Methods 0.000 description 86
• 230000014509 gene expression Effects 0.000 description 74
• 230000008878 coupling Effects 0.000 description 61
• 238000010168 coupling process Methods 0.000 description 61
• 241000699670 Mus sp. Species 0.000 description 46
• 235000018417 cysteine Nutrition 0.000 description 46
• 108060004872 MIF Proteins 0.000 description 45
• 102000034655 MIF Human genes 0.000 description 45
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 41
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 39
• 238000011282 treatment Methods 0.000 description 39
• 230000027455 binding Effects 0.000 description 36
• 241000699666 Mus <mouse, genus> Species 0.000 description 35
• 238000009739 binding Methods 0.000 description 35
• 238000003776 cleavage reaction Methods 0.000 description 35
• 230000007017 scission Effects 0.000 description 35
• 108010076504 Protein Sorting Signals Proteins 0.000 description 34
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
• 102000029797 Prion Human genes 0.000 description 31
• 108091000054 Prion Proteins 0.000 description 31
• 238000006243 chemical reaction Methods 0.000 description 31
• 239000000562 conjugate Substances 0.000 description 30
• 239000000047 product Substances 0.000 description 30
• 238000000746 purification Methods 0.000 description 30
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 28
• 239000013612 plasmid Substances 0.000 description 26
• 108010013369 Enteropeptidase Proteins 0.000 description 25
• 102100029727 Enteropeptidase Human genes 0.000 description 25
• 241001529936 Murinae Species 0.000 description 25
• 239000000872 buffer Substances 0.000 description 25
• 102000037865 fusion proteins Human genes 0.000 description 25
• 108020001507 fusion proteins Proteins 0.000 description 25
• 210000001744 T-lymphocyte Anatomy 0.000 description 24
• 102000005962 receptors Human genes 0.000 description 23
• 239000000243 solution Substances 0.000 description 22
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
• 239000008188 pellet Substances 0.000 description 21
• 210000003719 b-lymphocyte Anatomy 0.000 description 20
• 239000000499 gel Substances 0.000 description 20
• 208000015181 infectious disease Diseases 0.000 description 20
• 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 19
• 108091034117 Oligonucleotide Proteins 0.000 description 19
• 210000000234 capsid Anatomy 0.000 description 19
• 239000004971 Cross linker Substances 0.000 description 18
• 102000004127 Cytokines Human genes 0.000 description 18
• 108090000695 Cytokines Proteins 0.000 description 18
• 238000002965 ELISA Methods 0.000 description 18
• 230000001404 mediated effect Effects 0.000 description 17
• 239000011780 sodium chloride Substances 0.000 description 17
• 241001515965 unidentified phage Species 0.000 description 17
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
• 239000011541 reaction mixture Substances 0.000 description 15
• 239000000126 substance Substances 0.000 description 15
• 239000006228 supernatant Substances 0.000 description 15
• 238000002255 vaccination Methods 0.000 description 15
• 230000003612 virological effect Effects 0.000 description 15
• 108090000565 Capsid Proteins Proteins 0.000 description 14
• 102100023321 Ceruloplasmin Human genes 0.000 description 14
• 108091005804 Peptidases Proteins 0.000 description 14
• 239000004365 Protease Substances 0.000 description 14
• 238000010367 cloning Methods 0.000 description 14
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 13
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 230000004927 fusion Effects 0.000 description 13
• 230000003993 interaction Effects 0.000 description 13
• 239000003446 ligand Substances 0.000 description 13
• 235000019419 proteases Nutrition 0.000 description 13
• 241000894007 species Species 0.000 description 13
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
• 241000283690 Bos taurus Species 0.000 description 11
• 206010006187 Breast cancer Diseases 0.000 description 11
• 208000026310 Breast neoplasm Diseases 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 11
• 102100040247 Tumor necrosis factor Human genes 0.000 description 11
• 239000000178 monomer Substances 0.000 description 11
• 241001672158 Acinetobacter phage AP205 Species 0.000 description 10
• 241000894006 Bacteria Species 0.000 description 10
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
• 241000700159 Rattus Species 0.000 description 10
• 229920002684 Sepharose Polymers 0.000 description 10
• 206010003246 arthritis Diseases 0.000 description 10
• 230000001580 bacterial effect Effects 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 238000005119 centrifugation Methods 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 230000002163 immunogen Effects 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 230000002265 prevention Effects 0.000 description 10
• WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 108700026244 Open Reading Frames Proteins 0.000 description 9
• 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 210000000285 follicular dendritic cell Anatomy 0.000 description 9
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• 108091008874 T cell receptors Proteins 0.000 description 8
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 206010012601 diabetes mellitus Diseases 0.000 description 8
• 238000010790 dilution Methods 0.000 description 8
• 239000012895 dilution Substances 0.000 description 8
• 238000001493 electron microscopy Methods 0.000 description 8
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
• 210000000987 immune system Anatomy 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 238000001262 western blot Methods 0.000 description 8
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 7
• 108010070675 Glutathione transferase Proteins 0.000 description 7
• 102000005720 Glutathione transferase Human genes 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 241000238631 Hexapoda Species 0.000 description 7
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 7
• 241000725303 Human immunodeficiency virus Species 0.000 description 7
• 101000686907 Mus musculus Resistin Proteins 0.000 description 7
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 210000003979 eosinophil Anatomy 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000012528 membrane Substances 0.000 description 7
• 108020004999 messenger RNA Proteins 0.000 description 7
• -1 phosphoester Chemical class 0.000 description 7
• 210000003705 ribosome Anatomy 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 208000024827 Alzheimer disease Diseases 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 6
• 238000009010 Bradford assay Methods 0.000 description 6
• 108010074860 Factor Xa Proteins 0.000 description 6
• 101000686909 Homo sapiens Resistin Proteins 0.000 description 6
• 206010027476 Metastases Diseases 0.000 description 6
• 208000001132 Osteoporosis Diseases 0.000 description 6
• 101150044568 PRNP gene Proteins 0.000 description 6
• 101001018880 Rattus norvegicus Macrophage migration inhibitory factor Proteins 0.000 description 6
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
• 210000000805 cytoplasm Anatomy 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• 239000000428 dust Substances 0.000 description 6
• 125000000524 functional group Chemical group 0.000 description 6
• 210000002443 helper t lymphocyte Anatomy 0.000 description 6
• 102000056685 human RETN Human genes 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 230000035800 maturation Effects 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 230000009401 metastasis Effects 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 238000011144 upstream manufacturing Methods 0.000 description 6
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 5
• 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 101100298534 Mus musculus Prnp gene Proteins 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 241001494479 Pecora Species 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
• 239000001166 ammonium sulphate Substances 0.000 description 5
• 235000011130 ammonium sulphate Nutrition 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 238000000502 dialysis Methods 0.000 description 5
• 238000002523 gelfiltration Methods 0.000 description 5
• 102000053529 human TNFSF11 Human genes 0.000 description 5
• 210000003000 inclusion body Anatomy 0.000 description 5
• 239000012139 lysis buffer Substances 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
• 230000001681 protective effect Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 239000011347 resin Substances 0.000 description 5
• 229920005989 resin Polymers 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 108010082548 Chemokine CCL11 Proteins 0.000 description 4
• 102000006383 Chemokine CCL24 Human genes 0.000 description 4
• 108010083647 Chemokine CCL24 Proteins 0.000 description 4
• 102000019034 Chemokines Human genes 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 241000282326 Felis catus Species 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 208000008771 Lymphadenopathy Diseases 0.000 description 4
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
• 102000002067 Protein Subunits Human genes 0.000 description 4
• 108010090804 Streptavidin Proteins 0.000 description 4
• PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 238000001042 affinity chromatography Methods 0.000 description 4
• 150000001299 aldehydes Chemical group 0.000 description 4
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
• 230000000172 allergic effect Effects 0.000 description 4
• 229960000723 ampicillin Drugs 0.000 description 4
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
• 208000010668 atopic eczema Diseases 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 230000029087 digestion Effects 0.000 description 4
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
• 230000002209 hydrophobic effect Effects 0.000 description 4
• 230000036039 immunity Effects 0.000 description 4
• 239000012678 infectious agent Substances 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 208000018555 lymphatic system disease Diseases 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 229930182817 methionine Natural products 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 230000003472 neutralizing effect Effects 0.000 description 4
• 210000001322 periplasm Anatomy 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 229910052697 platinum Inorganic materials 0.000 description 4
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 230000003362 replicative effect Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 229930000044 secondary metabolite Natural products 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 108010087967 type I signal peptidase Proteins 0.000 description 4
• 210000000605 viral structure Anatomy 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
• 244000036975 Ambrosia artemisiifolia Species 0.000 description 3
• 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 3
• 208000037259 Amyloid Plaque Diseases 0.000 description 3
• 206010002198 Anaphylactic reaction Diseases 0.000 description 3
• 241000256844 Apis mellifera Species 0.000 description 3
• 241000271566 Aves Species 0.000 description 3
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 108010083702 Chemokine CCL21 Proteins 0.000 description 3
• 102000006435 Chemokine CCL21 Human genes 0.000 description 3
• 102000009016 Cholera Toxin Human genes 0.000 description 3
• 108010049048 Cholera Toxin Proteins 0.000 description 3
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• 210000000712 G cell Anatomy 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 102000016943 Muramidase Human genes 0.000 description 3
• 108010014251 Muramidase Proteins 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 241000219061 Rheum Species 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
• 108010067390 Viral Proteins Proteins 0.000 description 3
• 230000036783 anaphylactic response Effects 0.000 description 3
• 208000003455 anaphylaxis Diseases 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
• 238000000137 annealing Methods 0.000 description 3
• 235000003484 annual ragweed Nutrition 0.000 description 3
• 230000001772 anti-angiogenic effect Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 235000006263 bur ragweed Nutrition 0.000 description 3
• 239000004202 carbamide Substances 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 230000035605 chemotaxis Effects 0.000 description 3
• 238000011210 chromatographic step Methods 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 235000003488 common ragweed Nutrition 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 238000000635 electron micrograph Methods 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 230000035558 fertility Effects 0.000 description 3
• 230000003325 follicular Effects 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• 229960000789 guanidine hydrochloride Drugs 0.000 description 3
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
• 230000028996 humoral immune response Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000001024 immunotherapeutic effect Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 229960000274 lysozyme Drugs 0.000 description 3
• 239000004325 lysozyme Substances 0.000 description 3
• 235000010335 lysozyme Nutrition 0.000 description 3
• 201000004792 malaria Diseases 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 230000007171 neuropathology Effects 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000008520 organization Effects 0.000 description 3
• 210000002997 osteoclast Anatomy 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 235000009736 ragweed Nutrition 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000010839 reverse transcription Methods 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000011550 stock solution Substances 0.000 description 3
• 210000002536 stromal cell Anatomy 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 230000005951 type IV hypersensitivity Effects 0.000 description 3
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
• UNMSQGCYXOMOAC-UHFFFAOYSA-N 2-(n,2,4,6-tetranitroanilino)ethyl nitrate Chemical group [O-][N+](=O)OCCN([N+]([O-])=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O UNMSQGCYXOMOAC-UHFFFAOYSA-N 0.000 description 2
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
• 101710156159 50S ribosomal protein L21, chloroplastic Proteins 0.000 description 2
• 241000238876 Acari Species 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 102100034452 Alternative prion protein Human genes 0.000 description 2
• 208000004881 Amebiasis Diseases 0.000 description 2
• 206010001980 Amoebiasis Diseases 0.000 description 2
• 102400000344 Angiotensin-1 Human genes 0.000 description 2
• 101800000734 Angiotensin-1 Proteins 0.000 description 2
• 102000004881 Angiotensinogen Human genes 0.000 description 2
• 108090001067 Angiotensinogen Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 240000003291 Armoracia rusticana Species 0.000 description 2
• 235000011330 Armoracia rusticana Nutrition 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 235000018185 Betula X alpestris Nutrition 0.000 description 2
• 235000018212 Betula X uliginosa Nutrition 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• 101001106957 Bos taurus Ribonuclease pancreatic Proteins 0.000 description 2
• 244000025254 Cannabis sativa Species 0.000 description 2
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 201000006082 Chickenpox Diseases 0.000 description 2
• 241000606161 Chlamydia Species 0.000 description 2
• 102000001189 Cyclic Peptides Human genes 0.000 description 2
• 108010069514 Cyclic Peptides Proteins 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• 206010012335 Dependence Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 206010014612 Encephalitis viral Diseases 0.000 description 2
• 208000037487 Endotoxemia Diseases 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 108010053070 Glutathione Disulfide Proteins 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 206010019799 Hepatitis viral Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 2
• 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 102100021102 Hyaluronidase PH-20 Human genes 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 102100039897 Interleukin-5 Human genes 0.000 description 2
• 241000721668 Juniperus ashei Species 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• 208000004554 Leishmaniasis Diseases 0.000 description 2
• 241000714216 Levivirus Species 0.000 description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
• 208000016604 Lyme disease Diseases 0.000 description 2
• 239000007993 MOPS buffer Substances 0.000 description 2
• 101710138751 Major prion protein Proteins 0.000 description 2
• 201000005505 Measles Diseases 0.000 description 2
• 240000004658 Medicago sativa Species 0.000 description 2
• 101000960966 Mus musculus Interleukin-5 Proteins 0.000 description 2
• 101001018878 Mus musculus Macrophage migration inhibitory factor Proteins 0.000 description 2
• 206010029240 Neuritis Diseases 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 208000000474 Poliomyelitis Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 238000011579 SCID mouse model Methods 0.000 description 2
• 101150055528 SPAM1 gene Proteins 0.000 description 2
• 241000242680 Schistosoma mansoni Species 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 208000005448 Trichomonas Infections Diseases 0.000 description 2
• 206010044620 Trichomoniasis Diseases 0.000 description 2
• 206010046980 Varicella Diseases 0.000 description 2
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 201000009961 allergic asthma Diseases 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 230000002788 anti-peptide Effects 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 239000003125 aqueous solvent Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 229940105402 brillant blue Drugs 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000012412 chemical coupling Methods 0.000 description 2
• 238000010382 chemical cross-linking Methods 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• 229960005091 chloramphenicol Drugs 0.000 description 2
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 206010013663 drug dependence Diseases 0.000 description 2
• 241001493065 dsRNA viruses Species 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 210000003746 feather Anatomy 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 229960002143 fluorescein Drugs 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 102000044132 human CXCL13 Human genes 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 208000025095 immunoproliferative disease Diseases 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 239000002054 inoculum Substances 0.000 description 2
• 239000002919 insect venom Substances 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 238000011031 large-scale manufacturing process Methods 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000009630 liquid culture Methods 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 210000002751 lymph Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• 239000003147 molecular marker Substances 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 229920005615 natural polymer Polymers 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2
• 230000003071 parasitic effect Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 108010079891 prostein Proteins 0.000 description 2
• 239000012474 protein marker Substances 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 108091006084 receptor activators Proteins 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 229960003471 retinol Drugs 0.000 description 2
• 235000020944 retinol Nutrition 0.000 description 2
• 239000011607 retinol Substances 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 208000008864 scrapie Diseases 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 208000011117 substance-related disease Diseases 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 229920001059 synthetic polymer Polymers 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 229960000814 tetanus toxoid Drugs 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 239000013638 trimer Substances 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 201000008827 tuberculosis Diseases 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 231100000611 venom Toxicity 0.000 description 2
• 201000002498 viral encephalitis Diseases 0.000 description 2
• 201000001862 viral hepatitis Diseases 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
• JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
• ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
• SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
• CTRXDTYTAAKVSM-UHFFFAOYSA-N 3-{[ethyl({4-[(4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)(2-sulfophenyl)methylidene]cyclohexa-2,5-dien-1-ylidene})azaniumyl]methyl}benzene-1-sulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S(O)(=O)=O)C=CC=1N(CC)CC1=CC=CC(S(O)(=O)=O)=C1 CTRXDTYTAAKVSM-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 1
• 101150101112 7 gene Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
• 241000589291 Acinetobacter Species 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 241000256846 Apis cerana Species 0.000 description 1
• 241000256845 Apis dorsata Species 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 241000239223 Arachnida Species 0.000 description 1
• 241000726103 Atta Species 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• 241001136816 Bombus <genus> Species 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710098309 C-X-C motif chemokine 13 Proteins 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 108050006947 CXC Chemokine Proteins 0.000 description 1
• 102000019388 CXC chemokine Human genes 0.000 description 1
• 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 description 1
• 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 1
• 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
• 102100033620 Calponin-1 Human genes 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 101001047088 Canis lupus familiaris Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 101710117490 Circumsporozoite protein Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 102100034323 Disintegrin and metalloproteinase domain-containing protein 2 Human genes 0.000 description 1
• 101710116108 Disintegrin and metalloproteinase domain-containing protein 2 Proteins 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 101710082714 Exotoxin A Proteins 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 108010061711 Gliadin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 241001648387 Grevillea Species 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 239000004866 Hashish Substances 0.000 description 1
• 241000270431 Heloderma suspectum Species 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
• 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 241001562081 Ikeda Species 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
• 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000004559 Interleukin-13 Receptors Human genes 0.000 description 1
• 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
• 102000004554 Interleukin-17 Receptors Human genes 0.000 description 1
• 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 241000714210 Leviviridae Species 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 108010036176 Melitten Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 241000711408 Murine respirovirus Species 0.000 description 1
• 101000998145 Mus musculus Interleukin-17A Proteins 0.000 description 1
• 101001090203 Mus musculus Major prion protein Proteins 0.000 description 1
• 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
• 101000617124 Mus musculus Stromal cell-derived factor 1 Proteins 0.000 description 1
• 101000830602 Mus musculus Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
• 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 241000772415 Neovison vison Species 0.000 description 1
• 102000005348 Neuraminidase Human genes 0.000 description 1
• 108010006232 Neuraminidase Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 101100353036 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pme-1 gene Proteins 0.000 description 1
• 241000282943 Odocoileus Species 0.000 description 1
• 239000008896 Opium Substances 0.000 description 1
• 108010035042 Osteoprotegerin Proteins 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 101710116435 Outer membrane protein Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 239000008118 PEG 6000 Substances 0.000 description 1
• 101710190786 PI protein Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000004503 Perforin Human genes 0.000 description 1
• 108010056995 Perforin Proteins 0.000 description 1
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
• 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 description 1
• 102100033126 Phosphatidate cytidylyltransferase 2 Human genes 0.000 description 1
• 101710178746 Phosphatidate cytidylyltransferase 2 Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241001505293 Plasmodium ovale Species 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 206010036030 Polyarthritis Diseases 0.000 description 1
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
• 108700011066 PreScission Protease Proteins 0.000 description 1
• 102100032251 Pro-thyrotropin-releasing hormone Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 108010027767 Rank-Fc Proteins 0.000 description 1
• 108090000244 Rat Proteins Proteins 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 108700031620 S-acetylthiorphan Proteins 0.000 description 1
• 206010039438 Salmonella Infections Diseases 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
• 206010039587 Scarlet Fever Diseases 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 230000029662 T-helper 1 type immune response Effects 0.000 description 1
• WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• 241000767684 Thoe Species 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
• 241000223996 Toxoplasma Species 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102100039094 Tyrosinase Human genes 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 208000005475 Vascular calcification Diseases 0.000 description 1
• 241000256856 Vespidae Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000004931 aggregating effect Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 230000008369 airway response Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 229940074608 allergen extract Drugs 0.000 description 1
• 230000002009 allergenic effect Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 230000003941 amyloidogenesis Effects 0.000 description 1
• 230000000964 angiostatic effect Effects 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 239000003659 bee venom Substances 0.000 description 1
• 235000015278 beef Nutrition 0.000 description 1
• 235000013405 beer Nutrition 0.000 description 1
• IYXMNTLBLQNMLM-UHFFFAOYSA-N benzene-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C=C1 IYXMNTLBLQNMLM-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 102000023732 binding proteins Human genes 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000013575 birch pollen allergen Substances 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 210000004900 c-terminal fragment Anatomy 0.000 description 1
• 229930003827 cannabinoid Natural products 0.000 description 1
• 239000003557 cannabinoid Substances 0.000 description 1
• 229940065144 cannabinoids Drugs 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000002975 chemoattractant Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000007370 cognitive improvement Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
• 101150027734 cript gene Proteins 0.000 description 1
• 238000007821 culture assay Methods 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 239000013578 denaturing buffer Substances 0.000 description 1
• 238000010217 densitometric analysis Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000011033 desalting Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• 235000021312 gluten Nutrition 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 210000004209 hair Anatomy 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 102000043801 human CCL24 Human genes 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 150000003949 imides Chemical class 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000000951 immunodiffusion Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 108010008429 immunoglobulin-binding factors Proteins 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 230000017306 interleukin-6 production Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 210000001630 jejunum Anatomy 0.000 description 1
• BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000000629 knee joint Anatomy 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 102000003835 leukotriene receptors Human genes 0.000 description 1
• 108090000146 leukotriene receptors Proteins 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 210000003584 mesangial cell Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000007388 microgliosis Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000009707 neogenesis Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000004693 neuron damage Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 235000014571 nuts Nutrition 0.000 description 1
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 229960001027 opium Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 230000009543 pathological alteration Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 229940023041 peptide vaccine Drugs 0.000 description 1
• 229930192851 perforin Natural products 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000002572 peristaltic effect Effects 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 208000024335 physical disease Diseases 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 239000013573 pollen allergen Substances 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 208000030428 polyarticular arthritis Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 229940070376 protein Drugs 0.000 description 1
• 239000012562 protein A resin Substances 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000036647 reaction Effects 0.000 description 1
• 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
• 239000003237 recreational drug Substances 0.000 description 1
• 102000029752 retinol binding Human genes 0.000 description 1
• 108091000053 retinol binding Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 238000002702 ribosome display Methods 0.000 description 1
• 238000005096 rolling process Methods 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 206010039447 salmonellosis Diseases 0.000 description 1
• 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 231100000245 skin permeability Toxicity 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000011537 solubilization buffer Substances 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 229940043517 specific immunoglobulins Drugs 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 229940031626 subunit vaccine Drugs 0.000 description 1
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000007470 synaptic degeneration Effects 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
• 238000006177 thiolation reaction Methods 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 201000002311 trypanosomiasis Diseases 0.000 description 1
• 229960001005 tuberculin Drugs 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 241001534157 unclassified Levivirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000000264 venule Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 230000007501 viral attachment Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1